Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VizionfocusTPE:4771 -0.74%95 EV-to-EBITDA is 7.56 as of Sep. 13, 2026, which is 22% below its 10-year median of 9.70. GuruFocus rates TPE:4771 with a GF Score™ of 95/100 and a GF Value™ of NT$261.11 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 515 Medical Devices & Instruments companies, Vizionfocus ranks better than 75.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vizionfocus's enterprise value is NT$13,028 Mil.
Vizionfocus's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,723 Mil. Therefore, Vizionfocus's EV-to-EBITDA for today is 7.56.
The historical rank and industry rank for Vizionfocus's EV-to-EBITDA or its related term are showing as below:
TPE:4771'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.93 Med: 9.7 Max: 34.92
Current: 7.56
During the past 8 years, the highest EV-to-EBITDA of Vizionfocus was 34.92. The lowest was 6.93. And the median was 9.70.
TPE:4771's EV-to-EBITDA is ranked better than 75.53% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 13.63
vs TPE:4771: 7.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vizionfocus's PE Ratio (TTM) for today is calculated as:
Vizionfocus's share price for today is NT$201.50.
Vizionfocus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$15.098.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vizionfocus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4771 vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Vizionfocus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vizionfocus EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vizionfocus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vizionfocus's EV-to-EBITDA falls into.
Vizionfocus's current Enterprise Value is NT$13,028 Mil.
Vizionfocus's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,723 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vizionfocus (TPE:4771) has a EV-to-EBITDA of 7.56 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vizionfocus. This is 22% below median its historical median of 9.70. Over the past decade, Vizionfocus' EV-to-EBITDA has ranged from 6.93 to 34.92. According to the industry distribution chart, Vizionfocus ranks #126 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 24.5%.
Is Vizionfocus' EV-to-EBITDA too high?
Vizionfocus' current EV-to-EBITDA of 7.56 is 22% below median its 10-year median of 9.70. Over the past 10 years, this metric has ranged from a low of 6.93 to a high of 34.92. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.63. Vizionfocus' value of 7.56 is 44.5% below this industry median. Based on the distribution chart, Vizionfocus ranks #126 out of 515 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vizionfocus has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vizionfocus' EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Vizionfocus ranks #126 out of 515 companies for EV-to-EBITDA. This places Vizionfocus in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.63. Vizionfocus' value of 7.56 is 44.5% below this benchmark. Historically, Vizionfocus' own EV-to-EBITDA has ranged from 6.93 to 34.92 over the past decade. While the company's 10-year median is 9.70 vs. the industry median of 13.63, Vizionfocus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.63, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vizionfocus's current EV-to-EBITDA of 7.56 is 44.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vizionfocus. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vizionfocus's current EV-to-EBITDA is 7.56, which is 22% below median its own 10-year median of 9.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vizionfocus stock overvalued right now?
Based on GuruFocus' analysis, Vizionfocus (TPE:4771) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$261.11, compared to a current price of NT$201.50 — trading 22.8% below its estimated fair value. The current EV-to-EBITDA is 7.56, which is 22% below median its 10-year median of 9.70 and 44.5% below the Medical Devices & Instruments industry median of 13.63. Vizionfocus' overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vizionfocus (TPE:4771), the current EV-to-EBITDA is 7.56 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vizionfocus (TPE:4771) Overvalued in 2026?
Based on GuruFocus' analysis, Vizionfocus stock appears to be undervalued.
The current stock price of NT$201.50 is trading 22.8% below its estimated GF Value™ of NT$261.11.
GuruFocus considers Vizionfocus to be Modestly Undervalued.
Key valuation signals for TPE:4771:
EV-to-EBITDA: 7.56 (22% below median its 10-year median of 9.70)
GF Value™: NT$261.11 vs. price of NT$201.50 (22.8% below fair value)
Industry Position: 44.5% below the Medical Devices & Instruments median (#126 of 515)
No single metric tells the full story. See the TPE:4771 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vizionfocus Inc is mainly engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments, international trading, and other consulting services. The Company operates through the VIZIONFOCUS segment, which generates maximum revenue and is engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments, international trading, and other consulting services, and the Jiangsu Vizionfocus Inc. segment, whose main business includes the research and development, design, and production of contact lenses, as well as the wholesale, import, and export of related products.
95GF Score
Get the complete analysis for TPE:4771
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4771 has been successfully added to your 
